All In Biotech

Drug Trial Radar · NCT06741644

A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors

A Phase I/II, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS2009, a Tri-specific Antibody Targeting PD-1/VEGFA/CTLA-4, as Monotherapy and Combination Therapy in Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

800

Planned (sponsor's estimate)

Start

Feb 24, 2025

Primary completion

Jan 2027

Study completion Jan 2028

Sponsor

Lead sponsor
CStone PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Dec 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human (FIH), open-label, and multi-center Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS2009 as Monotherapy and Combination Therapy in Participants with Advanced Solid Tumors. The study is comprised of a Phase I dose escalation and Phase II dose expansion.

Conditions

  • Advanced Solid Tumors

Interventions

  • CS2009Drug

    CS2009 will be administered via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W).

  • CS2009Drug

    CS2009 will be administered via intravenous (IV) infusion on Day 1 of repeated 14/21-day cycles (Q2W/Q3W).

  • PemetrexedDrug

    IV infusion

  • CarboplatinDrug

    IV infusion

  • PaclitaxelDrug

    IV infusion

  • EtoposideDrug

    IV infusion

  • Nab-paclitaxelDrug

    IV infusion

  • OxaliplatinDrug

    IV infusion

  • CapecitabineDrug

    oral tablets

  • DocetaxelDrug

    IV infusion

  • LeucovorinDrug

    IV infusion

  • 5-FUDrug

    IV infusion

  • CisplatinDrug

    IV infusion

  • GemcitabineDrug

    IV infusion

  • IrinotecanDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. [Dose Escalation] Maximum tolerated dose (MTD) of CS2009Time frame: Cycle 1 (Up to 21 Days)
  2. [Dose Escalation] Tentative recommended Phase II dose (RP2D) of CS2009Time frame: Cycle 1 (Up to 21 Days)
  3. [Dose Escalation] Number of participants with adverse events (AEs)Time frame: Up to approximately 2 years
  4. [Dose Expansion] Objective response rate (ORR) evaluated by investigators per RECIST v1.1Time frame: Up to approximately 2 years

Locations

33 sites in 3 countries. Site status is shown where the registry gives one.

  • START Los Angeles, LLC

    Los Angeles, California · Recruiting

  • NEXT Dallas

    Irving, Texas · Recruiting

  • Alfred Hospital (Alfred Health)

    Melbourne, Australia · Recruiting

  • Austin Hospital (Austin Health)

    Melbourne, Australia · Recruiting

  • Monash Medical Centre (Monash Health)

    Melbourne, Australia · Recruiting

  • Peter Maccallum Cancer Centre Research

    Melbourne, Australia · Recruiting

  • Icon Cancer Centre South Brisbane

    South Brisbane, Australia · Recruiting

  • Blacktown Hospital

    Sydney, Australia · Recruiting

  • Macquarie University Hospital

    Sydney, Australia · Recruiting

  • Scientia Clinical Research Ltd

    Sydney, Australia · Recruiting

  • Beijing Cancer Hospital

    Beijing, China · Recruiting

  • Jilin Cancer Hospital

    Changchun, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, China · Recruiting

  • Sichuan Cancer Hospital

    Chengdu, China · Recruiting

  • West China Hospital of Sichuan University

    Chengdu, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, China · Recruiting

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, China · Recruiting

  • Sun Yat-Sen University Cancer Center

    Guangzhou, China · Recruiting

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, China · Not yet recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, China · Recruiting

  • Anhui Provincial Hospital

    Hefei, China · Recruiting

  • Central Hospital Affiliated to Shandong First Medical University

    Jinan, China · Recruiting

  • Linyi Cancer Hospital

    Linyi, China · Recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, China · Recruiting

  • Nanjing Drum Tower Hospital

    Nanjing, China · Recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, China · Recruiting

  • Shanghai East Hospital

    Shanghai, China · Recruiting

  • Shanghai Pulmonary Hospital

    Shanghai, China · Recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, China · Recruiting

  • Xuzhou Central Hospital

    Xuzhou, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, China · Recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.